Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation

Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.